Analyst Ratings For OncoSec Medical Inc (NASDAQ:ONCS)
Today, Maxim Group set its price target on OncoSec Medical Inc (NASDAQ:ONCS) to $5.00 per share.
There are 2 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on OncoSec Medical Inc (NASDAQ:ONCS) is Buy with a consensus target price of $4.00 per share, a potential 388.58% upside.
Some recent analyst ratings include
- 11/7/2018-OncoSec Medical Inc (NASDAQ:ONCS) gets downgraded to Neutral by Dawson James
- 11/7/2018-OncoSec Medical Inc (NASDAQ:ONCS) gets downgraded to Neutral by HC Wainwright
- 6/14/2017-OncoSec Medical Inc (NASDAQ:ONCS) had its Buy rating reiterated by Noble Financial
- 12/28/2016-OncoSec Medical Inc (NASDAQ:ONCS) has coverage initiated with a Buy rating
- On 11/20/2018 James M Demesa, Director, bought 8,500 with an average share price of $0.82 per share and the total transaction amounting to $6,970.00.
- On 11/7/2018 Daniel J O’connor, CEO, bought 10,000 with an average share price of $0.91 per share and the total transaction amounting to $9,100.00.
- On 11/7/2018 James M Demesa, Director, bought 1,500 with an average share price of $0.91 per share and the total transaction amounting to $1,365.00.
- On 7/5/2018 Avtar S Dhillon, Director, sold 37,575 with an average share price of $1.39 per share and the total transaction amounting to $52,229.25.
- On 7/5/2018 Richard B Slansky, CFO, sold 84,984 with an average share price of $1.39 per share and the total transaction amounting to $118,127.76.
- On 6/29/2018 Punit Dhillon, Director, sold 5,401 with an average share price of $1.38 per share and the total transaction amounting to $7,453.38.
- On 6/29/2018 Richard B Slansky, CFO, sold 2,420 with an average share price of $1.38 per share and the total transaction amounting to $3,339.60.
About OncoSec Medical Inc (NASDAQ:ONCS)
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.
Recent Trading Activity for OncoSec Medical Inc (NASDAQ:ONCS)
Shares of OncoSec Medical Inc closed the previous trading session at 0.82 −0.00090 0.11% with 1092053 shares trading hands.
